Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Ovarian Neoplasms 1 Neuroblastoma 1 Hepatoblastoma 1 Head and Neck Neoplasms 1 HER2 Positive Advanced Gastric Cancer 1 Basal Cell Carcinoma of the Head and Neck 1

Interventions

Cyclophosphamide 101 Etoposide 60 Carboplatin 55 Vincristine 51 Filgrastim 49 Topotecan 44 Temozolomide 44 Melphalan 44 Isotretinoin 44 Doxorubicin 44 Irinotecan 42 Cisplatin 35 Peripheral Blood Stem Cell Transplantation 31 dinutuximab 29 Radiotherapy 29 Granulocyte Colony-Stimulating Factor 29 sargramostim 28 3-Iodobenzylguanidine 27 Granulocyte-Macrophage Colony-Stimulating Factor 25 Busulfan 22 Magnetic Resonance Spectroscopy 19 aldesleukin 18 Thiotepa 18 fludarabine 17 Interleukin-2 17 humanized 3F8 anti-GD2 monoclonal antibody 16 etoposide phosphate 16 Ifosfamide 15 naxitamab 14 fludarabine phosphate 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neuroblastoma × Tissue Banks × Clear all

NCT04239040 2025-03-19

GVAX Plus Checkpoint Blockade in Neuroblastoma

Dana-Farber Cancer Institute

Phase 1 Terminated

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡